November 19, 2018

DS Biopharma announces DS107 patent grant in the US for the treatment of atopic dermatitis

Dublin, Ireland, November 19th 2018 – DS Biopharma (DS), a privately held clinical stage biopharmaceutical company specialising in the development of novel bioactive lipids, today announced […]
October 18, 2018

Oral DS107 found to reverse the molecular signature of moderate to severe atopic dermatitis patients in a phase 2 trial

Dublin, Ireland, October 18th 2018 – DS Biopharma (DS), a privately held biopharmaceutical company, today announced that oral treatment with DS107 reversed the molecular signature of […]
October 3, 2018

DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis

DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis Dublin, Ireland, October 3rd 2018 […]
December 11, 2017

DS Biopharma receives a patent allowance for DS109 in the US

Dublin, Ireland, December 11th, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced receipt of allowance for a patent application in the United […]
May 8, 2017

DS Biopharma appoints Professor Brendan Buckley as Non-Executive Director

Dublin, Ireland, May 8th, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced the appointment of Professor Brendan Buckley as a non-executive director […]
April 13, 2017

DS Biopharma receives a patent allowance for Oral DS107 in the US

Dublin, Ireland, April 13th, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced receipt of allowance for a patent application in the United […]
February 7, 2017

DS Biopharma appoints Jane Hollingsworth as Non-Executive Director

Dublin, Ireland, February 7, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced the appointment of Jane Hollingsworth as a non-executive director to […]